Generation Bio Co
Change company Symbol lookup
Select an option...
GBIO Generation Bio Co
PACB Pacific Biosciences of California Inc
OPCH Option Care Health Inc
OLFC Olfactory Biosciences Corp
OJSCY NK Rosneft' PAO
OCRNL NK Rosneft' PAO
OARFF Fort St James Nickel Corp
MDXG MiMedx Group Inc
CATY Cathay General Bancorp
EADSF Airbus SE
Go

Company profile

Generation Bio Co. is a genetic medicines company. The Company is developing a class of gene therapy utilizing its non-viral gene therapy platform to provide durable, redosable treatments for patients living with rare and prevalent diseases. The Company’s non-viral gene therapy platform includes its DNA construct called closed-ended DNA (ceDNA), its cell-targeted lipid nanoparticle delivery system (ctLNP) and its established, scalable capsid-free manufacturing process. The Company is developing gene therapies to provide targeted delivery of genetic payloads that include multiple genes to a range of tissues of diseases. The Company is also engineering its gene therapies to be redosable, which enable patient titration to reach the desired therapeutic expression and to maintain efficiency in a patient’s life. The Company is a preclinical stage company and have not identified a product candidate.

Closing Price
$30.11
Day's Change
2.73 (9.97%)
Bid
--
Ask
--
B/A Size
--
Day's High
30.40
Day's Low
27.31
Volume
(Light)
Volume:
222,012

10-day average volume:
397,213
222,012

Company Profile

Generation Bio Co. is a genetic medicines company. The Company is developing a class of gene therapy utilizing its non-viral gene therapy platform to provide durable, redosable treatments for patients living with rare and prevalent diseases. The Company’s non-viral gene therapy platform includes its DNA construct called closed-ended DNA (ceDNA), its cell-targeted lipid nanoparticle delivery system (ctLNP) and its established, scalable capsid-free manufacturing process. The Company is developing gene therapies to provide targeted delivery of genetic payloads that include multiple genes to a range of tissues of diseases. The Company is also engineering its gene therapies to be redosable, which enable patient titration to reach the desired therapeutic expression and to maintain efficiency in a patient’s life. The Company is a preclinical stage company and have not identified a product candidate.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
4.46x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

September 2020
Current Month
647.0K
Previous Month
459.1K
Percent of Float
1.68%
Days to Cover
6.5105 Days

Share Information

GBIO is in a share class of common stock
Float
39.4M
Shares Outstanding
46.4M
Institutions Holding Shares
58
66.71%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Jason RhodesChmn.
  • Cameron Geoffrey McDonoughPres.
  • Mark Angelino
  • Matthew NorkunasCFO
  • Doug KerrOther

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.